<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896154</url>
  </required_header>
  <id_info>
    <org_study_id>Fib-P-2012</org_study_id>
    <nct_id>NCT01896154</nct_id>
  </id_info>
  <brief_title>Pilot Study on Effect Size of Non-digestible Polysaccharides (NPS) on Immunity</brief_title>
  <acronym>Fib-P-2012</acronym>
  <official_title>A Randomized, Controlled Clinical Study on the Effect of Non-digestible Polysaccharides (NPS) on the Immune Response to Influenza Vaccination in Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Center Kiel GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Food &amp; Biobased Research - Wageningen UR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Teagasc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nofima</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioActor B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Oat Fiber AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Immitec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Research Center Kiel GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to estimate the effect size of a 5-week consumption period of&#xD;
      different dietary non-digestible polysaccharides (NPS) on antibody response to influenza&#xD;
      vaccination and cellular immunity of healthy volunteers (aged ≥ 50) for clarifying whether&#xD;
      these NPS may enable enhancement of immune defence and to estimate the sample size for a&#xD;
      confirmative trial. Furthermore the effects on faecal microbiota and its metabolites will be&#xD;
      investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is conducted in the frame of the collaborative project 'FibeBiotics' (Nr. 289517)&#xD;
      (Fibers as support of the Gut and Immune function of Elderly - From polysaccharide compound&#xD;
      to health claim) within the Seventh Framework Programme (FP7) for Research and Technological&#xD;
      Development of the European Union (EU).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean titre of antibodies against one of the 3 influenza strains in HI test</measure>
    <time_frame>3 weeks after vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Immunosenescence</condition>
  <arm_group>
    <arm_group_label>NPS from yeast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder containing the active ingredients (500mg NPS from yeast) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks. 2 weeks before vaccination and 3 weeks after vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPS from shiitake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder containing the active ingredient (500mg NPS from shitake) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPS from oat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder containing the active ingredient (10g NPS from oat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPS from wheat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder containing the active ingredient (10g NPS from wheat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPS from Lactobacillus mucosae</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder containing the active ingredient (2,3g NPS from L. mucosae) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12.0 g Maltodextrin and flavour with identical/similar appearance and taste (when mixed in drink), consumed once daily as described for the active products (NPS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>NPS</intervention_name>
    <description>Comparison of multiple dietary non-digestible polysaccharides</description>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_label>NPS from Lactobacillus mucosae</arm_group_label>
    <arm_group_label>NPS from oat</arm_group_label>
    <arm_group_label>NPS from shiitake</arm_group_label>
    <arm_group_label>NPS from wheat</arm_group_label>
    <arm_group_label>NPS from yeast</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Free-living postmenopausal woman and men aged ≥ 50 years willing to have influenza&#xD;
             vaccination season 2012/2013&#xD;
&#xD;
          -  willingness to abstain as far as possible from food and supplements containing&#xD;
             probiotics, prebiotic supplements, other fermented products, supplements containing&#xD;
             vitamins and minerals as well as willing to sustain on a low dietary fibre diet for 7&#xD;
             weeks.&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects enrolled in another clinical study in the last 4 weeks&#xD;
&#xD;
          -  Subjects already vaccinated against influenza during 2012-2013 with either the&#xD;
             influenza vaccine used in the present study or another influenza vaccine&#xD;
&#xD;
          -  vaccination against influenza within the previous 10 months&#xD;
&#xD;
          -  suffering from influenza or influenza-like illness within the previous 10 months&#xD;
&#xD;
          -  other vaccinations during and within 2 months before the study&#xD;
&#xD;
          -  symptoms of common infectious diseases (CID) of the airways or other organ systems&#xD;
             e.g. gastrointestinal tract in the last 4 weeks before inclusion&#xD;
&#xD;
          -  known congenital, acquired or iatrogenic immunodeficiency (e.g. HIV, chemotherapy,&#xD;
             immunosuppression)&#xD;
&#xD;
          -  active autoimmune diseases&#xD;
&#xD;
          -  allergy or hypersensitivity to any component of the vaccine (e. g. chicken egg&#xD;
             protein, certain antibiotics)(s. a. 9.2)&#xD;
&#xD;
          -  allergy or hypersensitivity to any component of the test product (e. g. yeast, gluten,&#xD;
             shiitake mushrooms)&#xD;
&#xD;
          -  allergy to latex&#xD;
&#xD;
          -  known coeliac disease (gluten enteropathy)&#xD;
&#xD;
          -  bowel movement less than 3 times per week&#xD;
&#xD;
          -  subjects, who meet 2 or more Rome III criteria for constipation or who take laxatives&#xD;
             on a regular basis&#xD;
&#xD;
          -  severe chronic disease (cancer, IBD, malabsorption, malnutrition, chronic inflammatory&#xD;
             diseases, renal, hepatic or cardiac diseases, COPD, respiratory insufficiency)&#xD;
&#xD;
          -  chronic abdominal pain&#xD;
&#xD;
          -  malformation of fingers&#xD;
&#xD;
          -  systemic treatment or topical treatment likely to interfere with evaluation of the&#xD;
             study parameters: antibiotics, intestinal or respiratory antiseptics, anti-rheumatics,&#xD;
             antiphlogistics (except aspirin or equivalent products preventing from aggregation of&#xD;
             platelets or blood clotting) and steroids prescribed in chronic inflammatory diseases&#xD;
&#xD;
          -  other treatments likely to interfere with study outcome (e.g. laxatives, body weight&#xD;
             management and/or medication)&#xD;
&#xD;
          -  treatments with calcium antagonists and nitrates and alpha blockers&#xD;
&#xD;
          -  diabetes mellitus on drug therapy&#xD;
&#xD;
          -  severe neurological, cognitive or psychiatric diseases&#xD;
&#xD;
          -  surgery or intervention requiring general anaesthesia within 2 months before the study&#xD;
&#xD;
          -  vegetarian, vegan&#xD;
&#xD;
          -  eating disorders (e.g. anorexia, bulimia)&#xD;
&#xD;
          -  alcohol and drug abuse&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  legal incapacity&#xD;
&#xD;
          -  blood parameters: Hb &lt; 12 g/dL Liver transaminases (ALT, AST) &gt; 2-fold increased Serum&#xD;
             creatinine &gt; 1,2 mg/dL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christiane Laue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center Kiel GmbH</affiliation>
  </overall_official>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dietary fibers, influenza vaccination, HI titres</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

